150619-90-2Relevant academic research and scientific papers
Sulfadiazine guanidyl derivatives: Synthesis, characterization and docking studies for potential antituberculosis agents
Bhat, Mahesh,Ganavi,Sagar,Vijay Shekar
, p. 2141 - 2144 (2018)
Due to the wide range of pharmacological and biological activities, guanidine considered as one of the attractive pharmacophores. The presence of -CN3 group in guanidine compounds makes them to have efficient affinity towards various substituents with wid
Synthesis of benzamide derivatives with thiourea-substituted benzenesulfonamides as carbonic anhydrase inhibitors
Tugrak, Mehtap,Gul, Halise Inci,Demir, Yeliz,Gulcin, Ilhami
, (2020/10/15)
The novel compounds with the chemical structure of N-({4-[N′-(substituted)sulfamoyl]phenyl}carbamothioyl)benzamide (1a–g) and 4-fluoro-N-({4-[N′-(substituted)sulfamoyl]phenyl}carbamothioyl)benzamide (2a–g) were synthesized as potent and selective human carbonic anhydrase (hCA) I and hCA II candidate inhibitors. The aryl part was changed to sulfacetamide, sulfaguanidine, sulfanilamide, sulfathiazole, sulfadiazine, sulfamerazine, and sulfametazine. The Ki values of compounds 1a–g were in the range of 20.73 ± 4.32 to 59.55 ± 13.07 nM (hCA I) and 5.69 ± 0.43 to 44.81 ± 1.08 nM (hCA II), whereas the Ki values of compounds 2a–g were in the range of 13.98 ± 2.57 to 75.74 ± 13.51 nM (hCA I) and 8.15 ± 1.5 to 49.86 ± 6.18 nM (hCA II). Comparing the Ki values of the final compounds and acetazolamide, compound 1c with the sulfanilamide moiety (Ki = 5.69 ± 0.43 nM, 8.8 times) and 2f with the sulfamerazine moiety (Ki = 8.15 ± 1.5 nM, 6.2 times) demonstrated promising and selective inhibitory effects against the hCA II isoenzyme, the main target protein in glaucoma. Furthermore, compounds 1d (Ki = 20.73 ± 4.32, 4 times) and 2d (Ki = 13.98 ± 2.57, 5.9 times), which have the sulfathiazole moiety, were found as potent hCA I inhibitors. Compounds 1c and 2f can be considered as the lead compounds determined in the present study, which can be investigated further to alleviate glaucoma symptoms.
